Environmental, Social & Governance Report

Overview

The report presents Brii Bio's 2024 ESG performance across public-health innovation, workforce, ethics and environmental operations. It highlights Breakthrough Therapy Designations for elebsiran and tobevibart, full intellectual-property rights acquired for BRII-179, and RMB249.8 million invested in R&D. The report also records more than 25% women on the Board, zero corruption or bribery instances, and no work-related fatal accident in the Group during the past three years. Environmental KPIs are reported for the China offices, including Scope 2 emissions, water consumption and non-hazardous waste.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 21 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services